The U.S. Food and Drug Administration ("FDA") accepted Celcuity's New Drug Application ("NDA") and granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026, ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel ...
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...
Asianet Newsable on MSN
What is 'zombie drug' that causes deadly wounds and overdose deaths, why experts call it global threat
Xylazine, a veterinary sedative, is now a growing global drug threat. Often mixed with opioids like fentanyl, it increases ...
"We are incredibly excited to be at AAD this year and to share the progress Revance has made across our entire aesthetics, regenerative and skincare portfolio," said Nadeem Moiz, CEO of Revance. "As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results